Design Therapeutics, Inc.

NASDAQ:DSGN

6.49 (USD) • At close December 26, 2024
Bedrijfsnaam Design Therapeutics, Inc.
Symbool DSGN
Munteenheid USD
Prijs 6.49
Beurswaarde 367,470,290
Dividendpercentage 0%
52-weken bereik 2.245 - 7.77
Industrie Biotechnology
Sector Healthcare
CEO Mr. Pratik Shah Ph.D.
Website https://www.designtx.com

An error occurred while fetching data.

Over Design Therapeutics, Inc.

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to

Vergelijkbare Aandelen

Erasca, Inc. logo

Erasca, Inc.

ERAS

2.62 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

18 USD

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

uniQure N.V. logo

uniQure N.V.

QURE

17.73 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

6.06 USD

Replimune Group, Inc. logo

Replimune Group, Inc.

REPL

12.79 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.266 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)